click below
click below
Normal Size Small Size show me how
Stack #100815
| Question | Answer |
|---|---|
| a drug substance is also called a | API active pharmaceutical ingredient that produces pharmacological activity |
| a new chemical NCE is a drug substance with | unknown clinical, toxicological physical and chemical properties. it is a API that has not been approved for marketing in the US |
| what stage or phase is a IND or investigational new drug application for human testing submitted to the FDA | preclinical stage |
| testing on animals to determin safety and efficacy | preclinical stage |
| after IND application is submitted where testing is done on health humans to determine tolerance and toxicity | phase one |
| less than 100 patients with condition | phase two |
| which phase is the drug formulation developed | phase two |
| large scale human studies | phase three |
| when is the NDA submitted to FDA | after clinical trials I-III |
| what is NDA | new drug application |
| what phase is after NDA submission but before approval to market often referred to as scale-up activities | phase IV |
| what does SUPAC stand for | scale up and post approval change |
| during phase five what can go on | product line extension new phsical form or strength changes but no use or indication changes |
| what does bioequivalent meen | have the same rate and extent of drug absorption |
| a generic must be the same in what 4 things | therapeutically eqv, same amount of drug, dosage form, and bioequivalent |
| what is a ANDA | abbreviated new drug application generic drug approval |
| what is general required instead of clinical trials | human bioequivalence studies (not preclinical or clinial toxcity or human safety studies) |
| ___is application for human testing:___is application for approval to market after clinical trials:___application for generica approval | IND, NDA, ANDA |
| manufacturer ensures finished dosage form has met all specification for inteneded use | ouality control |
| acceptance or rejection of incoming raw materials | quality control |
| system of facilities are aedquate and that written procedures are followed | quality assurance |
| coarse>colloidal >true | know the order |
| what three properties do colloids exhibit | tyndall, brownian movement, and electophoresis |
| sucrose, urea, gycerin and naphthalene are nonelectrolytes or electrolytes | nonelectroytes |
| HCl, sodium sulfate, ephedrine, phenobarbital | electrolytes |
| buffers are combinations of | weak acid and conjugate base (salt) or weak base and conjugate acid |
| henderson hasselbalch | ph=pka + log (salt/acid) |
| hermetic container | AIR TIGHT impervious to air or any other gas |
| there are glass types 1-3 that intended for parenteral products with __being the most resistant of leaching alkali from glass | type one |
| two problems with plastics | permeablity(dissoles plastic) and leaching(components of container enter content) |
| problem in plastic where binding of molecule to polymer materials | sorption |
| in vitro | lab setting |
| invivo | where you test bioavailablity in the systemic circulation of humans after its administration |
| preformulation studies define | the nature of the drug substance and framework for the drug's combination with pharmaceutical ingredients in fabrication of a dosage form |
| crystalline form vs amorphous in melting point | crystalline has orderly arranged units an show definited meling point |
| amyl nitrite | liquid that is volatile and flammable break glass and inhale |
| liquids cannot be formulatied in tablet form except | for nitroglycerine and scopolamine that is a solid salt form |
| increase solubility by | put into salt form, cosolvent complexation, micronization, solid dispersion |
| dissolution rate is usualy the rate limiting step | anything that will affect dissolution rate will also affect absorption |
| you can increase dessolution by | increasing solubility or decreasing size (ph is not an effective means of improving solubility |